Reaching The High Bar
Greetings to you Folks and Welcome Here. The purpose of this post really is to answer the following two questions that were posed to me after my last post Crossroads.
1. Can you imagine having the key to solving the ongoing mutations and the waste with ongoing vaccine trials? CYDY has the key and it’s being blocked and now we have the trail of evidence coming to light showing it all.
and
2. Quote: We sort of have a complexity in formation right now. Yes, and perhaps the complexity even more complex than described in your excellent essay. Not that I want to argue about your prudent call for burying the hatchet, separating Cytodyn 2.0 completely from its history with the agency and making ourselves liked by the FDA as respectful and obedient supplicant. But I see a problem here from THEIR point of view for giving us the green light. Suppose LL proves itself in one trial after another. Suppose its publicity as a potential platform miracle molecule keeps spreading. If so the history of LL will draw public attention as well. Public attention = journalistic and potentially legal investigations. Is it too farfetched to assume that thousands of families who lost their loved ones to Covid will take the agency to court when the DDDAV's shenanigans with CD10 and other acts of conspiracy against and sabotaging LL begin to surface? Could the agency as supremely and above all bureaucratic organization discount the dangers for itself lurking in LL history if and when they allow the molecule to shine? Just asking...
Both of these questions, although coming from two different shareholders on two different message boards, really asked the same question. Essentially, the questions ask that assuming leronlimab in fact does live up to all that it is cracked up to be, as per the vast array of researched journal articles on CCR5 blockade in so many different indications, then it shall in fact, inevitably produce a solid trail of stout evidence that clearly declares both its efficacy and safety. Given the existence of such a trail of indisputable evidence, doesn't it become logical to conclude that a curious not-too in-depth investigation into leronlimab's history gets carried out by the inquisitive public. Continuing along the same pattern of logic, wouldn't then, that investigation uncover at least some unfair bias which the administration was responsible for in opposition against leronlimab and against CytoDyn? If the answer to that is a resounding yes, it would, then why on Earth would the administration now be willing, even minimally, to favor and encourage CytoDyn at all with the knowledge that successful leronlimab trials and even a leronlimab approval might indirectly lead to an inquisitive and unwanted investigation into the history of leronlimab, and that could indirectly lead to the uncovering of the deep corruption and malpractices that have taken place against leronlimab and against CytoDyn exhibited in the actions of the administration?
At the time of this writing, I received 2 dislikes of my own reply on the Investor's Hangout question. I'd like to know the reason why I received those dislikes, but their owners did not say why they left the dislikes, so the only thing I can think is that my reply there was misunderstood, so the purpose of this post is to clear up any questions as to what I was meaning to say. I'm writing this post because I believe the questions posed above are valid questions and therefore, the answer too, need to be just as valid. The questions are a very real possibility of what could occur, so we can consider how such a situation might pan out. And like I always say, this is for the most part conjecture, however, based on what we know to be true.
It is becoming increasingly more and more difficult to deny that leronlimab was purposely cheated in its recent and distant history. The administration's accepted evidence of leronlimab's safety and efficacy is soon forthcoming in the publishing of (4) peer reviewed journal articles. (Take a look at minute mark 29:57 in the 5/30/24 Webcast for a timeline.) In a short time from now, CytoDyn's mCRC trial initiates, and leronlimab's efficacy in an Alzheimer's 20 patient trial as well as the results of the GlioBlastoma Multiforme Murine Study are to be made manifest, and these results do become illuminatingly clear and mind blowing. The results do clearly reveal leronlimab's pristine safety profile and its efficacy and ability to do the impossible when it comes to mCRC, GBM and Alzheimer's Disease.
As this awareness becomes increasingly more publicly manifest, and it will, then the knowledge of this drug spreads like wildfire amongst the Big Pharma community as well as throughout the circle of public discussion given the implications of these result findings in these indications. Shortly after that, as a result of the due diligence and research, these same public discussions now begin to turn against the administration because, that research would undoubtably uncover and disclose the fact that leronlimab has always been assuredly safe and has always been very effective in just about every indication it was tested and trialed in. So, then more questions are raised as to why the drug was never permitted to advance and why it was so vehemently held back.
After, some due diligence, the more inquisitive among these investigators come to learn exactly what we already know, that leronlimab was purposefully thwarted and cheated. The numbers of patients, citizens and shareholders that develop this realization swiftly increase and that leads to a tumult against the administration for the power they purposefully wielded against the drug and against the company while purposefully and willfully favoring drugs that are clearly inferior to leronlimab and even unworthy of treating the C-19 corona virus. The administration did things by unorthodox means when it came to dealing with the C-19 corona virus.
I've stated previously that they would stop at nothing to squash leronlimab and with the unfair changes made in the Remdesivir trial to the unfair changes made to the dosing in leronlimab's Covid trial where the required 4 doses were deviously and mischievously changed to only 2 doses, (minute 19:20), and that being only the tip of the iceberg of the litany of items which exhibit how unfairly leronlimab / CytoDyn was handled, treated and held in disfavor by the supposedly fair and just administration. Instead of a pure and righteous approach, their determined aim was ill directed to completely cut off CytoDyn from any chance of success in anything or any direction CytoDyn attempted to accomplish or pursue in the advancement of leronlimab.
As we know all too well, that despite everything that was done to this company, CytoDyn attempted to survive and to hold on because it believed wholeheartedly that leronlimab would still win in that COVID 19 trial, despite being purposefully handicapped. The company had to do what it had promised its shareholders it would do, so, they continued on in the trial despite their handicap, hoping leronlimab would squeeze a victory by anyway. Of course, CytoDyn missed statistical significance by a very tiny amount where the p value was just over 0.05, something like 0.053 which was 100% related to this imposed handicap and due to the unwarranted favor the administration allotted to Gilead despite leronlimab's clear advantages over Remdesivir. So, the administration was successful in what it wanted to accomplish. Recall the Warning Banner, the "Warning Letter" and how could the "Clinical Hold" be forgotten.
CytoDyn did not argue. It humbly accepted the discipline doled out by the administration. It knew that in the end, the work required to set this house in order would only set the record straight and they settled down to do the work which its CRO Amarex should have already done but did not do. Over the course of the next 2.5 years, CytoDyn did everything necessary to get the Clinical Hold lifted, a monumental task, along with the removal of the Warning Banner.
Today, as the FDA has lifted the Clinical Hold, CytoDyn is once again allowed to trial leronlimab and with the release of results of the ensuing trials, it soon becomes evident that leronlimab would have been the right choice in the recent past. That then leads to how unjustly CytoDyn was treated. When it becomes clearly evident, through the use of certain biomarkers and by the statistical clinical evidence which is coming, that leronlimab actually does everything it is purported to do, then, does it remain "hush hush" that had no bias originally occurred during those uncertain times when it appeared that leronlimab was hitting the mark, leronlimab would have made a massive difference in the course of world events. The course of the disease would have been greatly altered on the world stage had no bias been levied against it. Hundreds of thousands if not millions of sickened souls and dying individuals would have lived instead of died, all throughout the world including US citizens.
Did the administration intentionally interfere with leronlimab's advancement? Or is it clear cut that the administration did everything reasonable to insure that leronlimab was properly vetted before allowing it to be used against such a lethal disease like COVID 19? Especially when the possibility existed that it could have contributed to even more deaths. Does this raise further questions as to whether the administration intends on upholding the freedoms that CytoDyn requires in order to trial test its drug for future trials? It should.
Does the administration continue to cast disfavor upon CytoDyn while permitting inferior drugs to be scooted along on ahead of leronlimab? You almost get the feeling that there yet remains collusion at the highest levels. This trial going on right now is practically a duplicate of CytoDyn's Inflammation and Immune Activation trial, but with different endpoints. In practical terms, it is sabotage committed in plain daylight, yet it is permitted. The administration is 100% aware of the trial that they worked together with CytoDyn in favor of, and now Gilead somehow is running it, but with their drug instead of leronlimab against HIV while CytoDyn targets Inflammation and Immune Activation. It is becoming more and more clear as to who might be responsible for the majority of the collusion which CytoDyn finds itself in day after day.
This kind of information is not all that good for the administration. After all, they were appointed to be fair and just in their making of determinations about which drugs to approve and which to deny. The world and the country put their faith and trust in this administration. Yet, the infallible proof is coming that proves they chose to knowingly do the opposite. What was demanded of CytoDyn nearly killed it and nearly eliminated this life saving drug from ever having a chance of helping humanity while it is likely that the administration does not even receive a slap on the wrist. To ask them for an apology might get the drug banned all over again.
The mCRC trial protocol likely has been submitted and Dr. Lalezari says that takes 30 days to review and approve. The GBM murine study is already underway. Shareholders likely wait until early 2025 to begin the Alzheimer's 20 patient study. By permitting these to take place, so far, they are deciding in favor of leronlimab's advancement.
To me, it is quite interesting that Gilead wanted that same, very narrow spectrum patient population of cis-gender and transgender individuals. So few, but they wanted to prevent CytoDyn from even capturing that tiny patient population. It is almost as if they are saying, "If you want even that tiny patient population, you will have to submit to the shots that only we, Gilead call." Maybe they're saying, look, if you want peace with us, you need to do it our way, otherwise, it will be a struggle the whole way.
All of this chicanery and subterfuge is permitted. CytoDyn is permitted to trial while Gilead is permitted to capture that tiny patient population which both CytoDyn and the FDA agreed upon as necessary in order to lift the clinical hold. What is the end game? To obtain an unequivocally amazing lifesaving drug, that is perfectly prepared for buyout purposes? The rules seem to remain only enforceable against CytoDyn while BP is allowed to do as they wish. Why is Gilead interested in this tiny patient population other than to prevent CytoDyn's access to the HIV indication? The only problem is that CytoDyn is operating at a much higher level here, thanks to Jonah Sacha, PhD.
CytoDyn's advantage in cancer is that leronlimab is fully capable of treating MSS tumors, while Keytruda and the rest of the PD-1 blockers can only treat the MSI tumors. The MSI tumors only represent 15% of all the tumors while the MSS tumors represent 85% of the market. Most, if not all the MSS tumors are fatal, treatable only by chemotherapy. Leronlimab has the power to put an end to that and as of today, there is no cure to MSS type tumors, so there is no competitor in this market, so therefore, that is why CytoDyn has made mCRC Priority #1. The problem is that since there are no other competitors in this indication, how does CytoDyn partner as a combination therapy?
In addition, a true HIV PREP is in development, along with the development of an HIV CURE. Here CytoDyn is way ahead of the pack. A 3 month long-acting version of leronlimab with zero side effects for 3 straight months. Then rinse and repeat. A cure. An AAV derived version of leronlimab given once, but lasts forever, which CURES and eliminates any further capacity of getting HIV all without any side effects. How do these drugs compare to the current therapy?
Is Gilead so motivated to prevent CytoDyn's entry into the HIV market that they now want to block even the tiniest of patient populations and are willing to spend on yet another HIV trial so as to block CytoDyn even from capturing that? When is enough, enough? Will the big drug manufacturers all do like Gilead is doing in coercion against CytoDyn? How does the administration handle this corrupt collusive coercion when all this happens? Do they encourage it, or do they prove that in fact, they work for the people? Seems like things build up to a climax where the only thing that works as it should is leronlimab and all the other Expensive Band-Aids get rejected by the masses. At that point, their solutions utterly fail, one after the other while leronlimab fires on all cylinders.
CytoDyn reaches a point where it becomes crystal clear that leronlimab meets the mark that was set for it to reach. It hits the high mark on every jump. It fires on every cylinder. It wins in mCRC, in mTNBC, in Alzheimer's, in GBM and in MASH, and even Infectious Disease, in Inflammation and Immune Activation. On every front, it proves itself a winner. That is where this is headed.
When this happens, nobody on Earth needs to be told what happens next. When this happens, the writing is on the wall. It becomes clear as day what the next steps are. Together, almost in unison, they rise up against this molecule in whatever fashion they choose in an attempt to block its forward advancement. Everything that leronlimab does only validates our claims and research about it, but that only breeds more conflict and proves the administration is justified in its support and backing of CytoDyn. But the remainder of Big Pharma is dead set against the drug for months and months, and they request the administration to side with them. This causes a deep rift in the support for the administration. They expect the administration to be with them, but leronlimab's declaration of truth does not permit the administration to discount the outright plethora of lifesaving results.
Nobody has any idea of exactly when all of these good things finally come together which meet at the middle for leronlimab. If they did know, CytoDyn would not be permitted or enabled to walk this road from the get-go. Because, when all of these things begin to line up for leronlimab, all of the other competing things start to fall apart and begin to dismantle at the seams. This catches the administration's attention and because of it, they have no choice but to unabashedly approve and side with CytoDyn.
Greetings to you Folks and Welcome Here. The purpose of this post really is to answer the following two questions that were posed to me after my last post Crossroads.
1. Can you imagine having the key to solving the ongoing mutations and the waste with ongoing vaccine trials? CYDY has the key and it’s being blocked and now we have the trail of evidence coming to light showing it all.
and
2. Quote: We sort of have a complexity in formation right now. Yes, and perhaps the complexity even more complex than described in your excellent essay. Not that I want to argue about your prudent call for burying the hatchet, separating Cytodyn 2.0 completely from its history with the agency and making ourselves liked by the FDA as respectful and obedient supplicant. But I see a problem here from THEIR point of view for giving us the green light. Suppose LL proves itself in one trial after another. Suppose its publicity as a potential platform miracle molecule keeps spreading. If so the history of LL will draw public attention as well. Public attention = journalistic and potentially legal investigations. Is it too farfetched to assume that thousands of families who lost their loved ones to Covid will take the agency to court when the DDDAV's shenanigans with CD10 and other acts of conspiracy against and sabotaging LL begin to surface? Could the agency as supremely and above all bureaucratic organization discount the dangers for itself lurking in LL history if and when they allow the molecule to shine? Just asking...
Both of these questions, although coming from two different shareholders on two different message boards, really asked the same question. Essentially, the questions ask that assuming leronlimab in fact does live up to all that it is cracked up to be, as per the vast array of researched journal articles on CCR5 blockade in so many different indications, then it shall in fact, inevitably produce a solid trail of stout evidence that clearly declares both its efficacy and safety. Given the existence of such a trail of indisputable evidence, doesn't it become logical to conclude that a curious not-too in-depth investigation into leronlimab's history gets carried out by the inquisitive public. Continuing along the same pattern of logic, wouldn't then, that investigation uncover at least some unfair bias which the administration was responsible for in opposition against leronlimab and against CytoDyn? If the answer to that is a resounding yes, it would, then why on Earth would the administration now be willing, even minimally, to favor and encourage CytoDyn at all with the knowledge that successful leronlimab trials and even a leronlimab approval might indirectly lead to an inquisitive and unwanted investigation into the history of leronlimab, and that could indirectly lead to the uncovering of the deep corruption and malpractices that have taken place against leronlimab and against CytoDyn exhibited in the actions of the administration?
At the time of this writing, I received 2 dislikes of my own reply on the Investor's Hangout question. I'd like to know the reason why I received those dislikes, but their owners did not say why they left the dislikes, so the only thing I can think is that my reply there was misunderstood, so the purpose of this post is to clear up any questions as to what I was meaning to say. I'm writing this post because I believe the questions posed above are valid questions and therefore, the answer too, need to be just as valid. The questions are a very real possibility of what could occur, so we can consider how such a situation might pan out. And like I always say, this is for the most part conjecture, however, based on what we know to be true.
It is becoming increasingly more and more difficult to deny that leronlimab was purposely cheated in its recent and distant history. The administration's accepted evidence of leronlimab's safety and efficacy is soon forthcoming in the publishing of (4) peer reviewed journal articles. (Take a look at minute mark 29:57 in the 5/30/24 Webcast for a timeline.) In a short time from now, CytoDyn's mCRC trial initiates, and leronlimab's efficacy in an Alzheimer's 20 patient trial as well as the results of the GlioBlastoma Multiforme Murine Study are to be made manifest, and these results do become illuminatingly clear and mind blowing. The results do clearly reveal leronlimab's pristine safety profile and its efficacy and ability to do the impossible when it comes to mCRC, GBM and Alzheimer's Disease.
As this awareness becomes increasingly more publicly manifest, and it will, then the knowledge of this drug spreads like wildfire amongst the Big Pharma community as well as throughout the circle of public discussion given the implications of these result findings in these indications. Shortly after that, as a result of the due diligence and research, these same public discussions now begin to turn against the administration because, that research would undoubtably uncover and disclose the fact that leronlimab has always been assuredly safe and has always been very effective in just about every indication it was tested and trialed in. So, then more questions are raised as to why the drug was never permitted to advance and why it was so vehemently held back.
After, some due diligence, the more inquisitive among these investigators come to learn exactly what we already know, that leronlimab was purposefully thwarted and cheated. The numbers of patients, citizens and shareholders that develop this realization swiftly increase and that leads to a tumult against the administration for the power they purposefully wielded against the drug and against the company while purposefully and willfully favoring drugs that are clearly inferior to leronlimab and even unworthy of treating the C-19 corona virus. The administration did things by unorthodox means when it came to dealing with the C-19 corona virus.
I've stated previously that they would stop at nothing to squash leronlimab and with the unfair changes made in the Remdesivir trial to the unfair changes made to the dosing in leronlimab's Covid trial where the required 4 doses were deviously and mischievously changed to only 2 doses, (minute 19:20), and that being only the tip of the iceberg of the litany of items which exhibit how unfairly leronlimab / CytoDyn was handled, treated and held in disfavor by the supposedly fair and just administration. Instead of a pure and righteous approach, their determined aim was ill directed to completely cut off CytoDyn from any chance of success in anything or any direction CytoDyn attempted to accomplish or pursue in the advancement of leronlimab.
As we know all too well, that despite everything that was done to this company, CytoDyn attempted to survive and to hold on because it believed wholeheartedly that leronlimab would still win in that COVID 19 trial, despite being purposefully handicapped. The company had to do what it had promised its shareholders it would do, so, they continued on in the trial despite their handicap, hoping leronlimab would squeeze a victory by anyway. Of course, CytoDyn missed statistical significance by a very tiny amount where the p value was just over 0.05, something like 0.053 which was 100% related to this imposed handicap and due to the unwarranted favor the administration allotted to Gilead despite leronlimab's clear advantages over Remdesivir. So, the administration was successful in what it wanted to accomplish. Recall the Warning Banner, the "Warning Letter" and how could the "Clinical Hold" be forgotten.
CytoDyn did not argue. It humbly accepted the discipline doled out by the administration. It knew that in the end, the work required to set this house in order would only set the record straight and they settled down to do the work which its CRO Amarex should have already done but did not do. Over the course of the next 2.5 years, CytoDyn did everything necessary to get the Clinical Hold lifted, a monumental task, along with the removal of the Warning Banner.
Today, as the FDA has lifted the Clinical Hold, CytoDyn is once again allowed to trial leronlimab and with the release of results of the ensuing trials, it soon becomes evident that leronlimab would have been the right choice in the recent past. That then leads to how unjustly CytoDyn was treated. When it becomes clearly evident, through the use of certain biomarkers and by the statistical clinical evidence which is coming, that leronlimab actually does everything it is purported to do, then, does it remain "hush hush" that had no bias originally occurred during those uncertain times when it appeared that leronlimab was hitting the mark, leronlimab would have made a massive difference in the course of world events. The course of the disease would have been greatly altered on the world stage had no bias been levied against it. Hundreds of thousands if not millions of sickened souls and dying individuals would have lived instead of died, all throughout the world including US citizens.
Did the administration intentionally interfere with leronlimab's advancement? Or is it clear cut that the administration did everything reasonable to insure that leronlimab was properly vetted before allowing it to be used against such a lethal disease like COVID 19? Especially when the possibility existed that it could have contributed to even more deaths. Does this raise further questions as to whether the administration intends on upholding the freedoms that CytoDyn requires in order to trial test its drug for future trials? It should.
Does the administration continue to cast disfavor upon CytoDyn while permitting inferior drugs to be scooted along on ahead of leronlimab? You almost get the feeling that there yet remains collusion at the highest levels. This trial going on right now is practically a duplicate of CytoDyn's Inflammation and Immune Activation trial, but with different endpoints. In practical terms, it is sabotage committed in plain daylight, yet it is permitted. The administration is 100% aware of the trial that they worked together with CytoDyn in favor of, and now Gilead somehow is running it, but with their drug instead of leronlimab against HIV while CytoDyn targets Inflammation and Immune Activation. It is becoming more and more clear as to who might be responsible for the majority of the collusion which CytoDyn finds itself in day after day.
This kind of information is not all that good for the administration. After all, they were appointed to be fair and just in their making of determinations about which drugs to approve and which to deny. The world and the country put their faith and trust in this administration. Yet, the infallible proof is coming that proves they chose to knowingly do the opposite. What was demanded of CytoDyn nearly killed it and nearly eliminated this life saving drug from ever having a chance of helping humanity while it is likely that the administration does not even receive a slap on the wrist. To ask them for an apology might get the drug banned all over again.
The mCRC trial protocol likely has been submitted and Dr. Lalezari says that takes 30 days to review and approve. The GBM murine study is already underway. Shareholders likely wait until early 2025 to begin the Alzheimer's 20 patient study. By permitting these to take place, so far, they are deciding in favor of leronlimab's advancement.
To me, it is quite interesting that Gilead wanted that same, very narrow spectrum patient population of cis-gender and transgender individuals. So few, but they wanted to prevent CytoDyn from even capturing that tiny patient population. It is almost as if they are saying, "If you want even that tiny patient population, you will have to submit to the shots that only we, Gilead call." Maybe they're saying, look, if you want peace with us, you need to do it our way, otherwise, it will be a struggle the whole way.
All of this chicanery and subterfuge is permitted. CytoDyn is permitted to trial while Gilead is permitted to capture that tiny patient population which both CytoDyn and the FDA agreed upon as necessary in order to lift the clinical hold. What is the end game? To obtain an unequivocally amazing lifesaving drug, that is perfectly prepared for buyout purposes? The rules seem to remain only enforceable against CytoDyn while BP is allowed to do as they wish. Why is Gilead interested in this tiny patient population other than to prevent CytoDyn's access to the HIV indication? The only problem is that CytoDyn is operating at a much higher level here, thanks to Jonah Sacha, PhD.
CytoDyn's advantage in cancer is that leronlimab is fully capable of treating MSS tumors, while Keytruda and the rest of the PD-1 blockers can only treat the MSI tumors. The MSI tumors only represent 15% of all the tumors while the MSS tumors represent 85% of the market. Most, if not all the MSS tumors are fatal, treatable only by chemotherapy. Leronlimab has the power to put an end to that and as of today, there is no cure to MSS type tumors, so there is no competitor in this market, so therefore, that is why CytoDyn has made mCRC Priority #1. The problem is that since there are no other competitors in this indication, how does CytoDyn partner as a combination therapy?
In addition, a true HIV PREP is in development, along with the development of an HIV CURE. Here CytoDyn is way ahead of the pack. A 3 month long-acting version of leronlimab with zero side effects for 3 straight months. Then rinse and repeat. A cure. An AAV derived version of leronlimab given once, but lasts forever, which CURES and eliminates any further capacity of getting HIV all without any side effects. How do these drugs compare to the current therapy?
Is Gilead so motivated to prevent CytoDyn's entry into the HIV market that they now want to block even the tiniest of patient populations and are willing to spend on yet another HIV trial so as to block CytoDyn even from capturing that? When is enough, enough? Will the big drug manufacturers all do like Gilead is doing in coercion against CytoDyn? How does the administration handle this corrupt collusive coercion when all this happens? Do they encourage it, or do they prove that in fact, they work for the people? Seems like things build up to a climax where the only thing that works as it should is leronlimab and all the other Expensive Band-Aids get rejected by the masses. At that point, their solutions utterly fail, one after the other while leronlimab fires on all cylinders.
CytoDyn reaches a point where it becomes crystal clear that leronlimab meets the mark that was set for it to reach. It hits the high mark on every jump. It fires on every cylinder. It wins in mCRC, in mTNBC, in Alzheimer's, in GBM and in MASH, and even Infectious Disease, in Inflammation and Immune Activation. On every front, it proves itself a winner. That is where this is headed.
When this happens, nobody on Earth needs to be told what happens next. When this happens, the writing is on the wall. It becomes clear as day what the next steps are. Together, almost in unison, they rise up against this molecule in whatever fashion they choose in an attempt to block its forward advancement. Everything that leronlimab does only validates our claims and research about it, but that only breeds more conflict and proves the administration is justified in its support and backing of CytoDyn. But the remainder of Big Pharma is dead set against the drug for months and months, and they request the administration to side with them. This causes a deep rift in the support for the administration. They expect the administration to be with them, but leronlimab's declaration of truth does not permit the administration to discount the outright plethora of lifesaving results.
Nobody has any idea of exactly when all of these good things finally come together which meet at the middle for leronlimab. If they did know, CytoDyn would not be permitted or enabled to walk this road from the get-go. Because, when all of these things begin to line up for leronlimab, all of the other competing things start to fall apart and begin to dismantle at the seams. This catches the administration's attention and because of it, they have no choice but to unabashedly approve and side with CytoDyn.
2
